There has been unexpected increase in demand, but thankfully shortage of one brand has been resolved
Back in early June we reported that several formulations of fentanyl citrate had gone into shortage.
This is due to both manufacturing reasons and an unexpected increase in demand.
Most of these shortages were meant to resolve themselves by late June, however many are still continuing.
According to the TGA, current shortages include:
- Aspen fentanyl (as citrate) 100 microgram/2 mL solution for injection (to 15 August)
- Aspen fentanyl (as citrate) 500 microgram/10 mL solution for injection (to 31 August)
- Fentanyl GH Solution for Injection 100 microgram/2 mL ampoule (to 8 August)
- Fentanyl GH Solution for Injection 500 microgram/10 mL ampoule (to 15 September)
- DBL fentanyl 100 microgram/2mL (as citrate) injection USP ampoule (to 15 August)
- DBL fentanyl 500 microgram/10mL (as citrate) injection USP ampoule (to 31 July)
Two medicines products have had their shortage issue resolved:
- Astrazeneca fentanyl 100 microgram/2mL (as citrate) injection ampoule
- Astrazeneca fentanyl 500 microgram/10mL (as citrate) injection ampoule
“Wholesalers may have enough available stock of the medicine to cover anticipated shortages,” says the TGA.
“The predicted shortage start and end dates are included on the website as soon as the TGA receives the information from the sponsor.”